Uncovering the Role of CD4+ CAR T Cells in Cancer Immunotherapy
- 5 July 2023
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (17) , 2813-2815
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has transformed clinical care against blood malignancies and is seeing encouraging progress against solid tumors. While scientific advancement has been rapid, our mechanistic understanding of intrinsic features of CAR-engineered T cells is still evolving. CAR products typically consist of CD4+ and CD8+ T-cell subsets at variable ratios, yet a clear understanding of how each subset contributes together and independently to therapeutic response is lacking. CD8+ CAR T cells are well characterized for their perforin-dependent killing effects; however, the role of CD4+ CAR T cells as “helpers” versus “killers” has been variable across models and warrants more in-depth investigation. A recent study by Boulch and colleagues published in Nature Cancer demonstrates that CD4+ CAR T cells, alone, can exert potent antitumor activity through a mechanism involving IFNγ. CD4+ CAR T-cell production of IFNγ creates a cytokine field that can act at a distance to kill both antigen-positive and -negative tumor cells that are sensitive to the proapoptotic effects of IFNγ. These new findings reveal important insights for the antitumor effects mediated by CD4+ CAR T cells, which could have significant clinical implications.Keywords
This publication has 10 references indexed in Scilit:
- CD4+ T cell-induced inflammatory cell death controls immune-evasive tumoursNature, 2023
- Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activityNature Cancer, 2023
- CAR T cell killing requires the IFNγR pathway in solid but not liquid tumoursNature, 2022
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cellsNature, 2022
- IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous ImmunityCancer Discovery, 2021
- A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activityScience Immunology, 2021
- Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerCell, 2020
- Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γNature Cancer, 2020
- Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activityJCI Insight, 2018
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunityScience Translational Medicine, 2014